Barclays’s Novavax NVAX Stock Holding History

Barclays’s Portfolio NVAX Stock Details NVAX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q2	–	Sell	-100,000	Closed	-$478K	–	5174
2024 Q1	$478K	Sell	100,000 -290,000	-74%	-$1.34M	﹤0.01%	3624
2023 Q4	$1.87M	Buy	+390,000	New	+$2.39M	﹤0.01%	2968
2023 Q2	–	Sell	-7,400	Closed	-$51.3K	–	4929
2023 Q1	$51.3K	Sell	7,400 -2,100	-22%	-$19.3K	﹤0.01%	4435
2022 Q4	$97.7K	Buy	+9,500	New	+$168K	﹤0.01%	4236
2022 Q3	–	Sell	-174,900	Closed	-$8.99M	–	5035
2022 Q2	$8.99M	Buy	+174,900	New	+$9.06M	0.01%	1056
2019 Q2	–	Sell	-91,560	Closed	-$1.01M	–	7143
2019 Q1	$1.01M	Buy	91,560 +48,935	+115%	+$1.54M	﹤0.01%	3390
2018 Q4	$1.57M	Buy	+42,625	New	+$1.65M	﹤0.01%	2654
2017 Q1	–	Sell	-9,500	Closed	-$239K	–	6911
2016 Q4	$239K	Sell	9,500 -11,385	-55%	-$332K	﹤0.01%	4073
2016 Q3	$869K	Buy	20,885 +11,385	+120%	+$1.47M	﹤0.01%	2754
2016 Q2	$1.38M	Buy	+9,500	New	+$1.09M	﹤0.01%	2332
2015 Q4	–	Sell	-795	Closed	-$111K	–	6396
2015 Q3	$111K	Buy	+795	New	+$178K	﹤0.01%	4560

Other funds holding NVAX

SCM

Shah Capital Management Raleigh, North Carolina $526M AUM 46.41% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Sanofi Paris, France $534M AUM 205.96% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Coatue Management New York $48.6B AUM 94.27% 1-Year Est. Return

Barclays's NVAX Position: Q2 2026 in Review

Barclays reduced its Novavax (NVAX) stake by 88% in Q2 2026, selling an estimated $9.41M and leaving 140,967 shares worth $1.33M. The position accounts for ﹤0.01% of the portfolio, ranked #2621.

Barclays first reported a position in NVAX in Q2 2013 and has held it in 53 quarters since. The position peaked at $44.3M in Q2 2021. 267 funds tracked by Wall St. Rank hold NVAX as of Q2 2026.

Barclays held 140,967 shares of Novavax worth $1.33M as of Q2 2026.
Barclays sold 1,050,112 Novavax shares in Q2 2026, an estimated $9.41M.
Novavax made up ﹤0.01% of Barclays's portfolio in Q2 2026, its #2621 holding.
Barclays first reported a position in Novavax in Q2 2013 and has held it in 53 quarters since.
Barclays's Novavax position peaked at $44.3M in Q2 2021.
267 funds tracked by Wall St. Rank held Novavax as of Q2 2026.

Based on Barclays's 13F filing for Q2 2026, filed 14 Aug 2026.